KR900013949A - 정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도 - Google Patents

정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도 Download PDF

Info

Publication number
KR900013949A
KR900013949A KR1019900002912A KR900002912A KR900013949A KR 900013949 A KR900013949 A KR 900013949A KR 1019900002912 A KR1019900002912 A KR 1019900002912A KR 900002912 A KR900002912 A KR 900002912A KR 900013949 A KR900013949 A KR 900013949A
Authority
KR
South Korea
Prior art keywords
compound
tetrahydro
cis
naphthalene amine
dichlorophenyl
Prior art date
Application number
KR1019900002912A
Other languages
English (en)
Other versions
KR920005810B1 (ko
Inventor
케니쓰 코에 빌리
Original Assignee
알렌 제이.스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23244506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900013949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알렌 제이.스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이.스피겔
Publication of KR900013949A publication Critical patent/KR900013949A/ko
Application granted granted Critical
Publication of KR920005810B1 publication Critical patent/KR920005810B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 정신병치료, 소염 또는 면역억제 효과량의 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용되는 산부가 염을 정신병치료, 소염 또는 면역억제를 필요로 하는 포유동물에게 투여함을 포함하는, 상기 포유동물에서 정신병치료, 소염 또는 면역억제 효과를 얻는 방법 :
    상기식에서, R1은 수소 및 C1내지 C3알킬로 구성된 그룹중에서 선택되고, R2는 C1내지 C3알킬이고, Z는(여기에서, X와 Y는 각각 독립적으로 수소, 플루오로, 크로로, 브로모, 트리플루오로메틸, C1내지 C3의 알콕시 및 시아노로 구성된 그룹중에서 선택되고, X와 Y중 적어도 하나는 수소가 아니다)이고, W는 수소, 플루오로, 클로로, 브로모, 트리플루오로메틸 및 C1내지 C3의 알콕시로 구성된 그룹중에서 선택된다.
  2. 제1항에 있어서, 상기 화합물이 시스 또는 트란스 이성체인 방법.
  3. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  4. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-4-(4-클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  5. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-(3-트리플루오로메틸, 4-클로로-페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  6. 제1항에 있어서, 상기 화합물이 트란스-(1S) (1R)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  7. 제1항에 있어서, 상기 화합물이 트란스-(1S) (4S)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  8. 제1항에 있어서, 상기 화합물이 시스-(1S) (4R)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  9. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-아미노-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  10. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N,N-디메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  11. 정신병치료, 소염 또는 면역억제 효과량의 제1항의 화합물과 약학적으로 허용되는 담체를 함체 포함하는 정신병 및 염증치료와 면역억제 유도를 위한 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900002912A 1989-03-07 1990-03-06 정신병 치료제 KR920005810B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US320,014 1989-03-07
US07/320,014 US4981870A (en) 1989-03-07 1989-03-07 Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US320.014 1989-03-07

Publications (2)

Publication Number Publication Date
KR900013949A true KR900013949A (ko) 1990-10-22
KR920005810B1 KR920005810B1 (ko) 1992-07-20

Family

ID=23244506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900002912A KR920005810B1 (ko) 1989-03-07 1990-03-06 정신병 치료제

Country Status (17)

Country Link
US (2) US4981870A (ko)
EP (1) EP0386997B1 (ko)
JP (2) JPH0714870B2 (ko)
KR (1) KR920005810B1 (ko)
AT (1) ATE150299T1 (ko)
AU (1) AU610036B2 (ko)
CA (1) CA2011428C (ko)
DE (1) DE69030212T2 (ko)
DK (1) DK0386997T3 (ko)
HU (1) HU221624B1 (ko)
IE (1) IE81047B1 (ko)
IL (1) IL93576A (ko)
MY (1) MY106272A (ko)
NZ (1) NZ232800A (ko)
PH (1) PH26542A (ko)
PT (1) PT93351B (ko)
ZA (1) ZA901743B (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
WO1991009594A1 (en) * 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
ZA944513B (en) * 1993-06-23 1996-01-16 Cambridge Neuroscience Inc Sigma receptor ligands
ES2074946B1 (es) * 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
WO1999001121A1 (en) 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
CA2395231C (en) 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US6988556B2 (en) * 2002-02-19 2006-01-24 Halliburton Energy Services, Inc. Deep set safety valve
US7087785B2 (en) 2002-09-16 2006-08-08 Sepracor Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
EP1545485A2 (en) * 2002-09-16 2005-06-29 Sepracor Inc. Treatment of cns disorders with trans-4- (3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
RU2361862C2 (ru) * 2003-12-29 2009-07-20 Сепракор Инк. Пиррольные и пиразольные ингибиторы daao
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
CA2614282A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
US8053603B2 (en) * 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PT2816024T (pt) * 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Aminas quirais
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
RU2008152404A (ru) * 2006-05-31 2010-07-10 Сепракор Инк. (Us) Лечение болевых расстройств транс 4-(3, 4-дихлорфенил)-1, 2, 3, 4-тетрагидро-1-нафталинамином и его формамидом
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
RU2470011C2 (ru) 2007-05-31 2012-12-20 Сепракор Инк. Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
KR20170003677A (ko) * 2014-05-13 2017-01-09 선오비온 파마슈티컬스 인코포레이티드 Adhd의 치료를 위한 다소트랄린의 방법 및 조성물
CA2948839A1 (en) * 2014-05-13 2015-11-19 Sunovion Pharmaceuticals Inc. Dosage of dasotraline and method for treatment of adhd
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
FR3071726B1 (fr) * 2017-09-29 2020-09-04 Univ Paris Sud Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420472A (en) * 1972-09-27 1976-01-07 Pfizer Aminophenyltetralin compounds
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Also Published As

Publication number Publication date
DE69030212T2 (de) 1997-06-26
EP0386997B1 (en) 1997-03-19
ZA901743B (en) 1991-10-30
PH26542A (en) 1992-08-19
MY106272A (en) 1995-04-29
IE900798L (en) 1990-09-07
EP0386997A2 (en) 1990-09-12
AU5079690A (en) 1990-09-20
JPH07173056A (ja) 1995-07-11
JPH02300121A (ja) 1990-12-12
HU901325D0 (en) 1990-05-28
AU610036B2 (en) 1991-05-09
JP3020808B2 (ja) 2000-03-15
IL93576A (en) 1995-12-08
US5061728A (en) 1991-10-29
CA2011428C (en) 1994-11-08
DE69030212D1 (de) 1997-04-24
PT93351B (pt) 1996-03-29
US4981870A (en) 1991-01-01
NZ232800A (en) 1997-07-27
JPH0714870B2 (ja) 1995-02-22
ATE150299T1 (de) 1997-04-15
IL93576A0 (en) 1990-11-29
PT93351A (pt) 1990-11-07
IE81047B1 (en) 1999-12-01
KR920005810B1 (ko) 1992-07-20
HU221624B1 (hu) 2002-12-28
HUT59000A (en) 1992-04-28
EP0386997A3 (en) 1992-04-29
DK0386997T3 (da) 1997-04-14
CA2011428A1 (en) 1990-09-07

Similar Documents

Publication Publication Date Title
KR900013949A (ko) 정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도
KR910004572A (ko) 아자비시클로 퀴놀론 카르복실산
IL61374A0 (en) Derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions containing them
KR950031074A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR930019655A (ko) 종양치료 조성물 및 치료방법
ES8201948A1 (es) Un procedimiento para la preparacion de nuevos derivados transisomericos de 4-fenil-1,2,3,4- tetrahidro-1-naftalenamina.
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
PE20050130A1 (es) Compuestos organicos
AR018732A1 (es) Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene.
CO5560559A2 (es) Formulacion de suspension oral estabilizada
BR9610350A (pt) Tratamentos contra piolhos e misturas, loções e lìquidos para pulverização, repelentes de insetos.
DK1127571T3 (da) Anvendelse af sertralin til at behandle posttraumatisk stresssygdom
AR012426A1 (es) Un compuesto de indazol amida, un procedimiento para prepararlo, compuestos intermediarios, y una composicion farmaceutica que comprende dicho compuesto de indazol amida.
PE20081781A1 (es) Agonistas de adrenoreceptores alfa2c funcionalmente selectivos
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR950016723A (ko) 자가면역 질병의 억제 방법
ATE209177T1 (de) Von einem aromatischen oder heteroaromatischen radikal substituierte biphenylderivate und diese enthaltende pharmaceutische und kosmetische compositionen
KR930005972A (ko) N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민
AR033426A1 (es) Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento
KR950702554A (ko) 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents)
RU98106625A (ru) Производные колхицина и тиоколхицина, обладающие противовоспалительной и миорелаксирующей активностями
AR032653A1 (es) Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040701

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee